Heim207940 • KRX
add
Samsung Biologics Co Ltd
Við síðustu lokun
1.585.000,00 ₩
Dagbil
1.551.000,00 ₩ - 1.631.000,00 ₩
Árabil
982.000,00 ₩ - 1.987.000,00 ₩
Markaðsvirði
71,94 bn KRW
Meðalmagn
50,08 þ.
V/H-hlutf.
41,95
A/V-hlutfall
-
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (KRW) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 1,45 bn | 52,94% |
Rekstrarkostnaður | — | — |
Nettótekjur | — | — |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | 8,72 þ. | 25,60% |
EBITDA | — | — |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (KRW) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,46 bn | 12,13% |
Heildareignir | 11,06 bn | -36,20% |
Heildarskuldir | 3,61 bn | -43,88% |
Eigið fé alls | 7,45 bn | — |
Útistandandi hlutabréf | 54,52 m. | — |
Eiginfjárgengi | 11,60 | — |
Arðsemi eigna | — | — |
Ávöxtun eigin fjár | — | — |
Peningaflæði
Breyting á handbæru fé
| (KRW) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | — | — |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
Framkvæmdastjóri
Stofnsett
2011
Vefsvæði
Starfsfólk
5.195
